News

THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst...

Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently...

●       David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in...

● The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker...

Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science...

Mike brings decades of operational and board experience gained in Pharma, Biotech and Venture Capital to Theolytics Oxford, UK, March...

Theolytics presents data at ESMO on its lead program being developed for Ovarian Cancer ahead of first in human clinical trials anticipated

Oxford, UK, 9 June 2023 - Theolytics, a biotechnology company harnessing viruses to combat disease, today announces data presentations at...

Theolytics kick-starts a £1M project in collaboration with The University of Sheffield, supported by Innovate UK, to develop a novel...

We’re delighted to announce that we’re all taking part in the BioIndustry Association’s Research Relay 2021 to raise money for Ovarian...

Theolytics has been awarded a grant by Innovate UK, the UK’s innovation agency, to optimise their oncolytic virus candidate for treatment...

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies. Oxford,...